Zydus Lifesciences has recently informed exchanges that the company entered into a strategic agreement with CVS Caremark, a subsidiary of CVS Health. The agreement will see Zydus’ diabetes medications, Zituvio™ (sitagliptin), Zituvimet™ (sitagliptin and metformin hydrochloride), and Zituvimet™ XR (extended-release sitagliptin and metformin hydrochloride), added to CVS Caremark’s formulary starting January 1, 2025.
These products, approved by the US FDA under the 505(b)(2) route, are designed to improve glycemic control in adults with type 2 diabetes mellitus. Zituvio and its combination formulations include sitagliptin, a DPP-4 inhibitor, and metformin hydrochloride, a biguanide, both essential for managing diabetes when combined with diet and exercise.
Punit Patel, President & CEO of Zydus Pharmaceuticals USA Inc., expressed pride in collaborating with CVS Caremark, emphasizing the partnership’s role in enhancing patient access to quality medications while reducing costs. This collaboration underscores Zydus’ commitment to addressing the growing demand for effective diabetes treatments in the U.S. market, where the DPP-IV inhibitors market is valued at $10 billion (IQVIA™ Aug 2023).
